Cited by 581Lung Cancer Treatments and MutationsCancer Immunotherapy and BiomarkersLung Cancer Diagnosis and Treatment

The DOI matches its Crossref record; 27 of the 27 references it cites were found in a registry or an index.

A Phase II Study of Pembrolizumab in EGFR-Mutant, PD-L1+, Tyrosine Kinase Inhibitor Naïve Patients With Advanced NSCLC

Open access

Lisberg, A., Cummings, A., Goldman, J.W., Bornazyan, K., Reese, N., Wang, T., Coluzzi, P., Ledezma, B., Mendenhall, M., Hunt, J., Wolf, B., Jones, B., Madrigal, J., Horton, J., Spiegel, M., Carroll, J., Gukasyan, J., Williams, T., Sauer, L., Wells, C., Hardy, A., Linares, P., Lim, C., Ma, L., Adame, C., Garon, Edward B.·2018·Journal of Thoracic Oncology

DOI 10.1016/j.jtho.2018.03.035PMC PMC6063769

Open this paper in CoChat — free account Open PDF

Abstract

Background Despite the significant antitumor activity of pembrolizumab in NSCLC, clinical benefit has been less frequently observed in patients whose tumors harbor EGFR mutations compared to EGFR wild-type patients. Our single-center experience on the KEYNOTE-001 trial suggested that pembrolizumab-treated EGFR-mutant patients, who were tyrosine kinase inhibitor (TKI) naïve, had superior clinical outcomes to those previously treated with a TKI. As TKI naïve EGFR-mutants have generally been excluded from pembrolizumab studies, data to guide treatment decisions in this patient population is lacking, particularly in patients with programmed death ligand 1 (PD-L1) expression ≥50%.Methods We conducted a phase II trial (NCT02879994) of pembrolizumab in TKI naive patients with EGFR mutation-positive, advanced NSCLC and PD-L1-positive (≥1%, 22C3 antibody) tumors. Pembrolizumab was administered 200 mg every 3 weeks. The primary endpoint was objective response rate. Secondary endpoints included safety of pembrolizumab, additional pembrolizumab efficacy endpoints, and efficacy and safety of an EGFR TKI after pembrolizumab.Results Enrollment was ceased due to lack of efficacy after 11 of 25 planned patients were treated. Eighty-two percent of trial patients were treatment naïve, 64% had sensitizing EGFR mutations, and 73% had PD-L1 expression ≥50%. Only 1 patient had an objective response (9%), but repeat analysis of this patient's tumor definitively showed the original report of an EGFR mutation to be erroneous. Observed treatment-related adverse events were similar to prior experience with pembrolizumab, but two deaths within 6 months of enrollment, including one attributed to pneumonitis, were of concern.Conclusions Pembrolizumab's lack of efficacy in TKI naïve, PD-L1+, EGFR-mutant patients with advanced NSCLC, including those with PD-L1 expression ≥50%, suggests that it is not an appropriate therapeutic choice in this setting.

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Integrity signals

Registry

Crossref · 10.1016/j.jtho.2018.03.035

Cites

27 of 27 references verified0 citation errors · 0 not checkable

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1)
Eisenhauer, E. A., Therasse, P., Bogaerts, J., Schwartz, L. H., Sargent, D., Ford, R., Dancey, J., Arbuck, S., Gwyther, S., Mooney, M., et al. (2009) · European Journal of Cancer · doi:10.1016/j.ejca.2008.10.026 · Cited by 29,534
Activating Mutations in the Epidermal Growth Factor Receptor Underlying Responsiveness of Non–Small-Cell Lung Cancer to Gefitinib
Lynch, T. J., Bell, D. W., Sordella, R., Gurubhagavatula, S., Okimoto, R. A., Brannigan, B. W., Harris, P. L., Haserlat, S. M., Supko, J. G., Haluska, F. G., et al. (2004) · New England Journal of Medicine · doi:10.1056/nejmoa040938 · Cited by 11,486
EGFR Mutations in Lung Cancer: Correlation with Clinical Response to Gefitinib Therapy
Paez, J. G., Jänne, P. A., Lee, J. C., Tracy, S., Greulich, H., Gabriel, S., Herman, P., Kaye, F. J., Lindeman, N., Boggon, T. J., et al. (2004) · Science · doi:10.1126/science.1099314 · Cited by 9,368
Nivolumab versus docetaxel in advanced nonsquamous non-small-cell lung cancer
Borghaei, H., Paz-Ares, L., Horn, L., Spigel, D. R., Steins, M., Ready, N. E., Chow, L. Q., Vokes, E. E., Felip, E., Holgado, E., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1507643 · Cited by 9,335
Nivolumab versus Docetaxel in Advanced Squamous-Cell Non–Small-Cell Lung Cancer
Brahmer, J., Reckamp, K. L., Baas, P., Crinò, L., Eberhardt, W. E. E., Poddubskaya, E., Antonia, S., Pluzanski, A., Vokes, E. E., Holgado, E., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1504627 · Cited by 8,447
Gefitinib or Carboplatin–Paclitaxel in Pulmonary Adenocarcinoma
Mok, T. S., Wu, Y.-L., Thongprasert, S., Yang, C.-H., Chu, D.-T., Saijo, N., Sunpaweravong, P., Han, B., Margono, B., Ichinose, Y., et al. (2009) · New England Journal of Medicine · doi:10.1056/nejmoa0810699 · Cited by 8,261 · cited 1×
“Although this data suggests that TKI efficacy is not affected by preceding PD-1 axis inhibition, conclusions regarding the durability of this efficacy cannot be drawn at this time given the short median duration of TKI therapy in these patients (109 days).(23) Although our belief that patients with sensitizing EGFR mu…”
Mutational landscape determines sensitivity to PD-1 blockade in non–small cell lung cancer
Rizvi, N. A., Hellmann, M. D., Snyder, A., Kvistborg, P., Makarov, V., Havel, J. J., Lee, W., Yuan, J., Wong, P., Ho, T. S., et al. (2015) · Science · doi:10.1126/science.aaa1348 · Cited by 7,802
Self-citation
Pembrolizumab for the Treatment of Non–Small-Cell Lung Cancer
Garon, E. B., Rizvi, N. A., Hui, R., Leighl, N., Balmanoukian, A. S., Eder, J. P., Patnaik, A., Aggarwal, C., Gubens, M., Horn, L., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1501824 · Cited by 6,198
Self-citation
Osimertinib in Untreated EGFR -Mutated Advanced Non–Small-Cell Lung Cancer
Soria, J.-C., Ohe, Y., Vansteenkiste, J., Reungwetwattana, T., Chewaskulyong, B., Lee, K. H., Dechaphunkul, A., Imamura, F., Nogami, N., Kurata, T., et al. (2018) · New England Journal of Medicine · doi:10.1056/nejmoa1713137 · Cited by 5,508
Erlotinib in Previously Treated Non–Small-Cell Lung Cancer
Shepherd, F. A., Rodrigues Pereira, J., Ciuleanu, T., Tan, E. H., Hirsh, V., Thongprasert, S., Campos, D., Maoleekoonpiroj, S., Smylie, M., Martins, R., et al. (2005) · New England Journal of Medicine · doi:10.1056/nejmoa050753 · Cited by 5,419

Flagged first, then by citations

Show all 27 references

Research works printed but not linked: 3

Hellmann, 2015, MINI03.05 Efficacy of Pembrolizumab in Key Subgroups of Patients with Advanced NSCLC, J Thorac Oncol, 10, S261
Hu-Lieskovan S, et al. High Intratumoral T Cell Infiltration Correlated with Mutational Load and Response to Pembrolizumab in Non–Small Cell Lung Cancer. Paper presented at the 16th World Conference on Lung Cancer. Denver, Colorado: 2015.
Garon, 2015, Prior TKI therapy in NSCLC EGFR mutant patients associates with lack of response to anti-PD-1 treatment, J Thorac Oncol, 10, S269

Sorted by citations

Items 401–500 of 581

Downregulation of B7-H4 contributes to the synergistic effect of USP2a-targeted/anti-PD-1 combination therapy in EGFR mutant lung cancer
Sun, B., Kong, M., Jiang, X., Zhu, L., Zhang, J., Tan, L., Wang, C., Yuan, Z., Chen, S., Wang, C., et al. (2026) · Cancer Immunology Immunotherapy · doi:10.1007/s00262-026-04321-2 · Cited by 3
Durvalumab plus etoposide–platinum in patients with epidermal growth factor receptor (EGFR)-mutated advanced NSCLC and neuroendocrine transformation after first-line osimertinib: ORCHARD
Okamoto, I., Cho, B. C., Goldberg, S. B., Goldman, J. W., de Langen, A. J., Piotrowska, Z., Riess, J. W., Yu, H. A., Campelo, M. R. G., Cetnar, J. P., et al. (2026) · Lung Cancer · doi:10.1016/j.lungcan.2026.109501 · Cited by 3
Self-citation
Intracranial Efficacy of Atezolizumab, Bevacizumab, Carboplatin, and Paclitaxel in Real-World Patients with Non-Small-Cell Lung Cancer and EGFR or ALK Alterations
Rathbone, M., O’Hagan, C., Wong, H. H., Khan, A. M., Cook, T., Rose, S., Heseltine, J., & Escriu, C. (2024) · Cancers · doi:10.3390/cancers16071249 · Cited by 3
Improved survival for patients with lung cancer treated with perioperative immunotherapy
Presley, C. J., & Owen, D. H. (2024) · The Lancet · doi:10.1016/s0140-6736(24)01920-2 · Cited by 4
MAP1LC3C repression reduces CIITA- and HLA class II expression in non-small cell lung cancer
Barbeau, L. M. O., Beelen, N. A., Savelkouls, K. G. M., Keulers, T. G., Wieten, L., & Rouschop, K. M. A. (2025) · PLoS ONE · doi:10.1371/journal.pone.0316716 · Cited by 3
Exploring the Expression of CD73 in Lung Adenocarcinoma with EGFR Genomic Alterations
Long-Mira, É., Bontoux, C., Rignol, G., Hofman, V., Lassalle, S., Benzaquen, J., Boutros, J., Lalvée, S., Zahaf, K., Lespinet‐Fabre, V., et al. (2025) · Cancers · doi:10.3390/cancers17061034 · Cited by 3
The association of PD-L1 expression status and the PD-1/PD-L1 inhibitor-related toxicity profile in non-small cell lung cancer
Zhu, Q., Hu, H., OuYang, L.-Y., Yang, R., Wei, W., Huang, P., & He, X. (2025) · BMC Cancer · doi:10.1186/s12885-025-14218-5 · Cited by 3
Immunotherapy in Advanced Non-Small-Cell Lung Cancer with EGFR Mutations
Liu, F., Yuan, X., Jiang, J., & Chu, Q. (2020) · Immunotherapy · doi:10.2217/imt-2020-0148 · Cited by 3
Role of immunotherapy in metastatic EGFRm NSCLC
Dhabhar, B. N., Sahoo, T. P., & Akshay, J. K. (2022) · Indian Journal of Cancer · doi:10.4103/ijc.ijc_49_21 · Cited by 3
The efficacy of adding hyperthermia to the treatment of advanced NSCLC patients based on the states of EGFR
Zhou, Y., Zhong, Q., Huang, D., Li, Q., Huang, J. H., Wang, C., Chen, B., Chen, M., Li, Y., & Liu, W. (2022) · Aging · doi:10.18632/aging.204148 · Cited by 3
Targeted Therapy for Non–Small Cell Lung Cancer
Brea, E. J., & Rotow, J. K. (2023) · Hematology/Oncology Clinics of North America · doi:10.1016/j.hoc.2023.02.009 · Cited by 4
Efficacy of immune checkpoint inhibitors in non-small cell lung cancer with NTRK family mutations
Shang, X., Zhang, W., Han, W., Xia, H., Liu, G., Wang, X., & Liu, Y. (2023) · BMC Pulmonary Medicine · doi:10.1186/s12890-023-02707-x · Cited by 3
Stage as the Sole “Biomarker” for Adjuvant Pembrolizumab in Resected Stage IB to IIIA NSCLC without Considerations for PD-L1 Expression Level, ALK/EGFR Mutational Status, and Prior Adjuvant Chemotherapy per FDA Approval Indications of PEARLS/Keynote-091?
Nagasaka, M., & Ou, S. I. (2023) · Lung Cancer Targets and Therapy · doi:10.2147/lctt.s433195 · Cited by 3
Are lung adenocarcinoma mutations shaping the immune microenvironment?
Rochigneux, P., & Garon, E. B. (2018) · Translational Cancer Research · doi:10.21037/tcr.2018.07.17 · Cited by 3
Self-citation
Efficacy and safety of pembrolizumab monotherapy in EGFR-mutant squamous cell lung cancer with PD-L1 over-expression: A case report
Liu, Q., Wei, J.-G., Chen, Y., & Wang, J. (2022) · Medicine · doi:10.1097/md.0000000000030099 · Cited by 3
Approach to stage IV non-small-cell lung cancer: how to select among first-line therapy options?
Pacheco, J. M. (2019) · Current Opinion in Pulmonary Medicine · doi:10.1097/mcp.0000000000000659 · Cited by 3
Treatment of Patients With Non–Small-Cell Lung Cancer Harboring Rare Oncogenic Mutations
Marmarelis, M. E., & Langer, C. J. (2020) · Clinical Lung Cancer · doi:10.1016/j.cllc.2020.01.010 · Cited by 3
Immunothérapie des cancers bronchiques non à petites cellules métastatiques, de la première ligne à la résistance et sa prise en charge
Basse, C., Swalduz, A., Levra, M. G., Girard, N., Remón, J., & Moro‐Sibilot, D. (2020) · Bulletin du Cancer · doi:10.1016/j.bulcan.2020.04.018 · Cited by 3
Identification of a Microsatellite Stable, EGFR-Mutant Lung Adenocarcinoma Developing in a Patient With Lynch Syndrome
Hissong, E. M., Baek, I., Costa, V. A., Beneck, D. M., Saxena, A., Solomon, J. P., & Song, W. (2020) · JCO Precision Oncology · doi:10.1200/po.20.00074 · Cited by 3
Role of immune checkpoint blockers in patients with EGFR mutation
Ward, J. P., & Morgensztern, D. (2018) · Translational Lung Cancer Research · doi:10.21037/tlcr.2018.09.13 · Cited by 2
KEYNOTE-042 rolls back programmed cell death ligand 1 threshold for non-small cell lung cancer pembrolizumab monotherapy without new insight into those deriving benefit
Cummings, A. L., & Garon, E. B. (2019) · Translational Lung Cancer Research · doi:10.21037/tlcr.2019.07.06 · Cited by 2
Self-citation
Erlotinib plus bevacizumab for EGFR-mutant advanced non-squamous non-small-cell lung cancer patients: ready for first-line?
Adderley, H., Ackermann, C. J., & Califano, R. (2019) · Annals of Translational Medicine · doi:10.21037/atm.2019.09.116 · Cited by 2
Immune and Genomic Heterogeneity of MET-Altered Non–Small Cell Lung Cancer
Liu, M., Minne, R. L., Javeri, S., Johnson, D. B., Tomlins, S. A., Kimple, R. J., & Baschnagel, A. M. (2025) · JCO Precision Oncology · doi:10.1200/po-25-00048 · Cited by 2
Knowledge mapping and visualization of immune checkpoint inhibitor-related pneumonitis: a bibliometric analysis
Jiang, Y., Xu, M., Xu, S., & Wu, Q. (2025) · Discover Oncology · doi:10.1007/s12672-025-03769-5 · Cited by 2
Atezolizumab + Chemotherapy for Advanced Non‐Small Cell Lung Cancer in Japanese Clinical Practice (J‐TAIL‐2)
Yoshioka, H., Nishio, M., Ohashi, K., Osoegawa, A., Kikuchi, E., Kimura, H., Goto, Y., Shimizu, J., Miyauchi, E., Yoshino, I., et al. (2025) · Cancer Science · doi:10.1111/cas.70242 · Cited by 2
Real-world analysis of subsequent-line strategies for EGFR C797S mutant non-small cell lung cancer patients acquired resistance to third-generation EGFR tyrosine kinase inhibitors
Xu, J., Zhu, A., Xu, Y., Zhang, Y., Shen, Y., Niu, Y., Zhong, H., & Zhong, R. (2025) · BMC Cancer · doi:10.1186/s12885-025-15335-x · Cited by 3
Comprehensive clinical characteristics and outcomes of stage IV EGFR-mutant NSCLC based on PD-L1 expression
Lee, J. W., Jin, X., Bogdan, S., Abou-Alfa, A., Chang, J., Rafizadeh, M., Kang, E. C., Garcia, C., Zhou, X. K., & Saxena, A. (2026) · Cancer Treatment and Research Communications · doi:10.1016/j.ctarc.2026.101109 · Cited by 2
PD ‐ L1 Expression and Histopathological Features in EGFR ‐Mutated Non‐Small Cell Lung Cancer: Implications for Immune Checkpoint Inhibitors After EGFR ‐Tyrosine Kinase Inhibitors Resistance
Sumi, T., Ishigooka, T., Matsuura, K., Ikeda, T., Yamada, Y., Arioka, K., & Chiba, H. (2026) · Thoracic Cancer · doi:10.1111/1759-7714.70252 · Cited by 2
Afatinib Versus Osimertinib for Non‐Small Cell Lung Cancer With Uncommon EGFR Mutations: Real‐World Outcomes
Nagano, Y., Yokouchi, H., Saito, R., Honjo, O., Sumi, T., Kaburagi, T., Ito, K., Ikezawa, Y., Yokoo, K., Kikuchi, H., et al. (2026) · Cancer Science · doi:10.1111/cas.70400 · Cited by 2
[Research Progress of Immune Checkpoint Inhibitor Therapy for BRAF Mutation in Non-small Cell Lung Cancer].
Liu, X., & Zhong, D. (2019) · PubMed Central · doi:10.3779/j.issn.1009-3419.2019.09.06 · Cited by 3
Role of Surgical Pathologist for the Detection of Immuno-oncologic Predictive Factors in Non-small Cell Lung Cancers
Mohanty, S. K., Mishra, S. K., Amin, M. B., Agaimy, A., & Fuchs, F. S. (2023) · Advances in Anatomic Pathology · doi:10.1097/pap.0000000000000395 · Cited by 3
Updating the Targeted Therapy Paradigm for Patients With Metastatic NSCLC
Narjust Florez, M., & Mcdonald, S. (2023) · Journal of the Advanced Practitioner in Oncology · doi:10.6004/jadpro.2023.14.3.12 · Cited by 3
[Progress of Immunotherapy in EGFR-mutated Advanced Non-small Cell Lung Cancer].
Liu, Y., & Miao, J. (2024) · PubMed Central · doi:10.3779/j.issn.1009-3419.2023.106.26 · Cited by 2
Prognostic Factors in Japanese EGFR Mutation-Positive Non-Small-Cell Lung Cancer: A Real-World Single-Center Retrospective Cohort Study
Takashima, K., Wakabayashi, H., Murakami, Y., Saiki, A., & Matsuzawa, Y. (2024) · Drugs - Real World Outcomes · doi:10.1007/s40801-024-00449-8 · Cited by 2
Efficacy and safety of camrelizumab plus famitinib in patients with previously treated non-small-cell lung cancer: a single-arm, phase II trial
Gao, M., Zhang, X., Yan, H., Zhao, Y., Yuan, F., Sun, D., Yang, X., Ju, Y., Wang, L., Tao, H., et al. (2025) · Therapeutic Advances in Medical Oncology · doi:10.1177/17588359241311058 · Cited by 2
Lack of clearly defined role for anti-programmed death-(ligand) 1 therapy in epidermal growth factor receptor mutated non-small cell lung cancer
Lisberg, A. E., & Garon, E. B. (2019) · Translational Lung Cancer Research · doi:10.21037/tlcr.2019.02.01 · Cited by 2
Self-citation
Is an immune checkpoint inhibitor really a hopeless therapeutic choice for EGFR-mutant non-small cell lung cancer (NSCLC) patients?
Kunimasa, K., Nishino, K., & Kumagai, T. (2019) · Annals of Translational Medicine · doi:10.21037/atm.2019.02.18 · Cited by 2
[Molecular Mechanism of Different Signaling Pathways in Regulating PD-L1 Expression in EGFR Mutated Lung Adenocarcinoma].
Leng, X., Mei, J., & Liu, L. (2018) · Europe PMC (PubMed Central) · doi:10.3779/j.issn.1009-3419.2018.11.10 · Cited by 2
Successful immune checkpoint inhibition in an EGFR-mutant lung cancer patient refractory to epidermal growth factor receptor tyrosine kinase inhibitor treatment
Hochmair, M. J., Weinlinger, C., & Prosch, H. (2020) · Anti-Cancer Drugs · doi:10.1097/cad.0000000000000876 · Cited by 2
First‐line immune checkpoint therapy in metastatic squamous cell lung cancer harboring both EGFR mutation and high expression of PD‐L1 : A case report
Hamai, K., Tanahashi, H., Ueno, S., Konishi, H., Matsumura, M., Nomura, A., Nakamoto, K., Isoyama, S., Tanimoto, T., Shoda, H., et al. (2020) · Thoracic Cancer · doi:10.1111/1759-7714.13436 · Cited by 2
[Retracted] Clinical Efficacy and Safety Analysis of PD‐1/PD‐L1 Inhibitor vs. Chemotherapy in the Treatment of Advanced Non‐Small‐Cell Lung Cancer: A Systematic Review and Meta‐Analysis
Guo, W., Zhang, T.-W., Wang, B.-L., Mao, L.-Q., & Li, X.-B. (2022) · BioMed Research International · doi:10.1155/2022/9500319 · Cited by 2
Retracted
Immunotherapies in the management of epidermal growth factor receptor mutated non-small cell lung cancer: a role will be found?
Casaluce, F., & Gridelli, C. (2018) · Translational Lung Cancer Research · doi:10.21037/tlcr.2018.09.18 · Cited by 2
[Research Advances of EGFR-TP53 Co-mutation in Advanced Non-small Cell Lung Cancer].
Wang, R., Pan, S., & Song, X. (2022) · PubMed Central · doi:10.3779/j.issn.1009-3419.2022.101.06 · Cited by 2
Exploring the Role of Immunotherapy-Based Treatments for Advanced Non–Small-Cell Lung Cancer With Novel Driver Alterations
Brambilla, M., Beninato, T., Piemontese, A., Mazzeo, L., Pircher, C. C., Manglaviti, S., Ambrosini, P., Signorelli, D., Lorenzini, D., Prelaj, A., et al. (2023) · Clinical Lung Cancer · doi:10.1016/j.cllc.2023.08.004 · Cited by 2
Osimertinib plus Ramucirumab: The Best of Both Worlds?
Garon, E. B. (2021) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-20-4026 · Cited by 2
Self-citation
Targeted adjuvant therapy in non-small cell lung cancer: trick or treat?
Hendriks, L. E. L., van Meerbeeck, J. P., & Cadranel, J. L. (2021) · European Respiratory Journal · doi:10.1183/13993003.01637-2021 · Cited by 2
Cons: should immunotherapy be incorporated in the treatment of oncogene-driven lung cancer?
Metro, G., & Maïo, M. D. (2018) · Translational Lung Cancer Research · doi:10.21037/tlcr.2018.07.12 · Cited by 2
Unmet Clinical Demand for Patients With Unresectable Stage III NSCLC Having Actionable Genetic Alterations
Liu, S. M., & Wu, Y.-L. L. C. (2021) · Journal of Thoracic Oncology · doi:10.1016/j.jtho.2021.02.020 · Cited by 2
Increased Tumor Mutation Burden Levels and Sensitivity of Non–Small Cell Lung Cancer to PD-L1 Blockade—Reply
Ricciuti, B., Wang, X., & Awad, M. M. (2023) · JAMA Oncology · doi:10.1001/jamaoncol.2022.7589 · Cited by 2
Another Pirate in the Red Ocean? CD73-Targeted Therapy in EGFR-Mutated NSCLC
Horinouchi, H. (2023) · Journal of Thoracic Oncology · doi:10.1016/j.jtho.2023.02.002 · Cited by 2
FLAURA strikes again: efficacy of osimertinib is independent of PD-L1 expression
Abdayem, P., & Planchard, D. (2020) · Translational Lung Cancer Research · doi:10.21037/tlcr-20-628 · Cited by 1
ROS1
Oesterich, L. G., & Riess, J. W. (2019) · Current cancer research · doi:10.1007/978-3-030-17832-1_3 · Cited by 1
Neoadjuvant targeted therapy versus targeted combined with chemotherapy for resectable EGFR-mutant non–small cell lung cancer: a retrospective controlled real-world study
Shao, W., Liu, Z., Li, B., Chen, F., Liu, J., Li, H., & Guo, H. (2024) · Frontiers in Oncology · doi:10.3389/fonc.2024.1349300 · Cited by 1
Surgeon preferences for self-treatment in locally advanced non–small cell lung cancer: Would we practice what we preach?
Brunelli, A., Antonoff, M. B., Petersen, R. H., Stiles, B. M., Wigle, D. A., Platz, J. J., Muesse, J. L., Louie, B. E., Grenda, T. R., Daddi, N., et al. (2024) · Journal of Thoracic and Cardiovascular Surgery · doi:10.1016/j.jtcvs.2024.05.029 · Cited by 1
Durvalumab, Tremelimumab, and Platinum Chemotherapy in EGFR Mutation–Positive NSCLC: An Open-Label Phase 2 Trial (ILLUMINATE)
Lee, C. K., Liao, B.-C., Subramaniam, S., Chiu, C., Mersiades, A. J., Ho, C., Brown, C. S. B., Lai, C., Hughes, B. G. M., Yang, T., et al. (2024) · JTO Clinical and Research Reports · doi:10.1016/j.jtocrr.2024.100771 · Cited by 1
Neoadjuvant Immunochemotherapy for Stage II-IIIB Non-Small Cell Lung Cancer With Mutations Beyond EGFR 19del, L858R, and ALK Rearrangement
Ding, H., Tao, B., Xu, L., Jiang, G., & Wang, H. (2025) · The Annals of Thoracic Surgery · doi:10.1016/j.athoracsur.2025.04.016 · Cited by 1
First-line immunotherapy in advanced non-squamous non-small cell lung cancer patients with rare mutations: a retrospective cohort study
Cao, W., Kou, F., Hu, W., Hu, L., Nie, J., Dai, L., Zhang, J., Rui, J., Knetki‐Wróblewska, M., Antonoff, M. B., et al. (2025) · Translational Lung Cancer Research · doi:10.21037/tlcr-2025-716 · Cited by 1
HSP90 inhibition induces oncogenic EGF receptor degradation to suppress cell growth in non-small cell lung cancer
Zhu, Y., Wang, P., Li, Y., Wang, J., Wang, L., Cheng, S., Zhang, Y., Yang, Y., Jialiang, S., Zhang, Y., et al. (2025) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2025.178105 · Cited by 1
Platelet indices as prognostic biomarkers in lung cancer: A meta-analysis and Mendelian randomization study
Yuan, M., Chen, H. Q., Liu, Z., Zheng, Y., Liu, S., Zhang, G., & Yang, G. (2026) · Medicine · doi:10.1097/md.0000000000047550 · Cited by 1
Single-cell spatial analysis stratifies lung adenocarcinoma with rare actionable mutations and reveals immune-modulatory cellular crosstalk
Ma, J., Li, X., Qian, N., Li, S., Li, L., Zhang, X., Su, L., Yang, Y., Luo, H., Yin, M., et al. (2026) · Cell Reports Medicine · doi:10.1016/j.xcrm.2026.102760 · Cited by 1
Mutant-Selective T-cell Receptor Therapy for Solid Tumors
Parry, S. R., Jang, C., Leal, A., & Punekar, S. R. (2026) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-23-0894 · Cited by 1
Efficacy and mechanisms of immune checkpoint inhibitors in late-stage EGFR-mutated non-small cell lung cancer following targeted therapy resistance
Niu, J., Jing, W., Liu, Z., Si, Y., & 刘寨东 (2026) · Frontiers in Immunology · doi:10.3389/fimmu.2026.1845547 · Cited by 1
Sequencing Therapies in Oncogene-Driven Non-Small-Cell Lung Cancer: How to Get The Best Mileage?
Sukrithan, V., Snyder, R. B., Cheng, H., & Halmos, B. (2019) · Future Oncology · doi:10.2217/fon-2019-0103 · Cited by 1
[Advances in the Influence of EGFR Mutation on the PD-L1 Expression in Non-small Cell Lung Cancer].
Zhi, X., Li, W., Wang, S., & Wang, J. (2019) · PubMed · doi:10.3779/j.issn.1009-3419.2019.12.08 · Cited by 1
Clinical outcomes of Atezolizumab Therapy for Previously-Treated Advanced-Stage Non-Small Cell Lung Cancer: A Real-World Study in Taiwan
Wu, S., Chiang, C., Wang, C., Hung, J., Hsia, T., Kuo, C. S., & Shih, J. (2022) · Journal of Cancer · doi:10.7150/jca.74617 · Cited by 1
[Advances in ICIs Therapy after TKIs Resistance in Patients with EGFR Mutant NSCLC: A Review].
Chen, R., Jiang, C., Ma, L., & Zhang, S. (2022) · PubMed Central · doi:10.3779/j.issn.1009-3419.2022.101.37 · Cited by 1
Self-citation
Interventional pulmonology use of cell-free DNA assay for metastatic non–small cell lung cancer: the UC Davis experience
Phan, C. T., Jespersen, F., Weipert, C. M., Li, T., & Yoneda, K. Y. (2022) · Therapeutic Advances in Respiratory Disease · doi:10.1177/17534666221135324 · Cited by 1
Diagnostic value of programmed cell death-ligand 1 expression on circulating tumor cells in lung cancer: A systematic review and meta-analysis
Cui, M., Wan, Z., Yang, J., Liao, D., Yang, Y., & Xiang, Y. (2023) · The International Journal of Biological Markers · doi:10.1177/03936155231192674 · Cited by 1
Long response to camrelizumab in metastatic lung squamous cell carcinoma with high PD-L1 expression despite EGFR G719S mutation: A case report
Wang, Y., & Fang, K. (2023) · Tropical Journal of Pharmaceutical Research · doi:10.4314/tjpr.v22i7.24 · Cited by 1
Histo-Molecular Factors of Response to Combined Chemotherapy and Immunotherapy in Non-Small Cell Lung Cancers
Marchal, M., Leroy, V., Béhal, H., Dansin, É., Paris, N., Bordier, S., Humez, S., Escande, F., Gauvain, C., & Cortot, A. B. (2023) · Targeted Oncology · doi:10.1007/s11523-023-01009-w · Cited by 1
Clinical factors and major pathological response after neoadjuvant chemoimmunotherapy in potentially resectable lung squamous cell carcinoma
Wang, Y., Song, Y., Wang, R., Wu, Y., Li, M., Xu, K., He, R., Wang, Z., Li, Q., Kong, F., et al. (2024) · Frontiers in Oncology · doi:10.3389/fonc.2024.1265228 · Cited by 2
Self-citation
Top 20 EGFR+ NSCLC Clinical and Translational Science Papers That Shaped the 20 Years Since the Discovery of Activating EGFR Mutations in NSCLC. An Editor-in-Chief Expert Panel Consensus Survey.
Ou, S. I., Le, X., Nagasaka, M., Reungwetwattana, T., Ahn, M., Lim, W., Santos, E. S., Shum, E., Lau, S. C. M., Lee, J. B., et al. (2024) · Lung Cancer Targets and Therapy · doi:10.2147/lctt.s463429 · Cited by 1
Impact of Tobacco, Marijuana, and Alcohol Use on Overall Survival in Recurrent Metastatic Head and Neck Cancer Patients Treated With Immune Checkpoint Inhibitors
Alsavaf, M. B., Issa, M., Klamer, B. G., Husain, M., Dibs, K. N., Pan, X. J., Grecula, J. C., Old, M. O., Konieczkowski, D. J., Mitchell, D., et al. (2024) · Asia-Pacific Journal of Clinical Oncology · doi:10.1111/ajco.14135 · Cited by 3
Perioperative Treatment in EGFR ‐Mutant Early‐Stage Non‐Small Cell Lung Cancer: Current Evidence and Future Perspectives
Guo, X., Liu, X., Guo, C., Miao, Q., Cheng, X., Hong, X., Li, H., Qiu, X., Xiang, Y., Di, Z., et al. (2025) · Thoracic Cancer · doi:10.1111/1759-7714.70018 · Cited by 1
Response of EGFR-mutated pulmonary pleomorphic carcinoma to pembrolizumab
Hatakeyama, Y., Mizugaki, H., Yamada, N., Mizukami, Y., Kuwahara, K., Asahina, H., Adachi, H., Yokouchi, H., Matsuno, Y., & Oizumi, S. (2025) · Respiratory Medicine Case Reports · doi:10.1016/j.rmcr.2025.102234 · Cited by 1
Lung cancer
Isaacs, J. M., & Clarke, J. M. (2022) · Elsevier eBooks · doi:10.1016/b978-0-12-800684-9.00006-x · Cited by 1
Effectiveness of Second-Line Pembrolizumab Monotherapy for the Treatment of Nonsmall Cell Lung Cancer: A Retrospective-Single Institution Study of 52 Vietnamese Patients
Nguyen, T. V., Hung, K. D., Le, Q. V., Do, A. T., Nguyen, C. V., Nguyen, T. B. P., & Nguyen, T. N. H. (2025) · Clinical Medicine Insights Oncology · doi:10.1177/11795549251359142 · Cited by 1
A retrospective analysis of immunotherapy in non-small cell lung cancer patients with targetable genetic mutations
Zhang, S., Liu, J., Liu, J., & Lu, K. (2025) · Medicine · doi:10.1097/md.0000000000044144 · Cited by 1
[A Single Center Analysis of Advanced Non-small Cell Lung Cancer Patients Treated with Immunotherapy in Real-world Practice].
Liu, Y., Zhang, T., Gao, Y. J., Qu, Y., Lu, B., Zhang, H., Wang, Q., Li, J., Hu, F., & Li, B. (2019) · PubMed Central · doi:10.3779/j.issn.1009-3419.2019.11.02 · Cited by 1
Good response with durvalumab after chemoradiotherapy for epidermal growth factor receptor exon 20 insertion adenocarcinoma: A case report
Matsuura, S., Morikawa, K., Ito, Y., Kagoo, N., Kubota, T., Ichijo, K., Mochizuki, E., Uehara, M., Harada, M., Tsukui, M., et al. (2020) · Respiratory Medicine Case Reports · doi:10.1016/j.rmcr.2020.101236 · Cited by 1
Imaging Pattern of Diffuse Intrapulmonary Metastases in Lung Cancer Was Associated with Poor Prognosis to Epidermal Growth Factor Receptor Inhibitors
Fu, Y., Tang, Y., Zheng, Y., Chen, Y., Hong, Y., Wang, P., Li, Q., Liu, T., & Ding, Z. (2020) · Cancer Management and Research · doi:10.2147/cmar.s261983 · Cited by 1
Radical Resection for Second EGFR-mutated Primary Lung Cancer Following Immune Checkpoint Inhibitor Monotherapy for Stage IV Lung Adenocarcinoma
Horibe, R., Hatakeyama, T., Ishikawa, T., Sawai, T., Hashimoto, M., Domen, H., Takakuwa, Y., Satoh, M., & Nishiyama, K. (2021) · Internal Medicine · doi:10.2169/internalmedicine.6385-20 · Cited by 1
EGFR-Directed Therapy in Lung Cancer
Kim, S. Y., Costa, D. B., Shibahara, D., Kobayashi, S. S., & Halmos, B. (2023) · Cambridge University Press eBooks · doi:10.1017/9781009342285
A Rare EGFR R748T Mutation in A Squamous Cell Lung Carcinoma Patient with PD-L1 High Expression and Response to Immuno-Chemo Combination TherapyPreprint
Sun, R., Duan, Q., Lei, G., & Liu, Z. (2020) · Research Square · doi:10.21203/rs.3.rs-68851/v1 · Cited by 1
What is the current role of immunotherapy in EGFR mutant advanced NSCLC?
Velez, M. A., Tsai, H. H. C., Shackelford, D. B., Garon, E. B., & Lisberg, A. E. (2021) · Lung Cancer · doi:10.1016/j.lungcan.2021.12.001 · Cited by 1
Self-citation
Integrative Analysis of Checkpoint Blockade Response in Advanced Non-Small Cell Lung CancerPreprint
Ravi, A., Gainor, J. F., Arniella, M. B., Holton, M., Freeman, S. S., Stewart, C., Leshchiner, I., Kim, J., Akiyama, Y., Griffin, A. T., et al. (2022) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2022.03.21.485199 · Cited by 1
The Distribution Characteristics and Dynamic Changes of Gut Microbiota Indicates the Efficacy of Immunotherapy in Advanced EGFR-Mutated Non-Small Cell Lung CancerPreprint
Luo, W., Mei, S., Huang, Z., Chen, Z., Zhang, Y., Yang, M., Liu, J., Xu, J.-Y., Yang, X., Zhong, R.-W., et al. (2024) · SSRN Electronic Journal · doi:10.2139/ssrn.4681862 · Cited by 1
Obesity shapes selection for driver mutations in cancerPreprint
Tang, C., Castillon, V. J., Waters, M., Fong, C., Park, T., Boscenco, S., Kim, S., Schultz, N. D., Ostrovnaya, I., Gusev, A., et al. (2024) · medRxiv · doi:10.1101/2024.01.10.24301114 · Cited by 1
A novel prediction model for immunotherapy induced pneumonitis prediction based on Chest CT and electronic health recordPreprint
Lyu, Q., Yuan, H., Lin, Z., Ponnatapura, J., & Whitlow, C. T. (2024) · medRxiv · doi:10.1101/2024.10.14.24315487 · Cited by 1
Competing Immune Biomarkers in the Selection of First-line Therapy in Non-small Cell Lung Cancer
Tolba, K. A. (2018) · touchREVIEWS in Oncology & Haematology · doi:10.17925/ohr.2018.14.2.67
Cas clinique n° 5 : Adaptation thérapeutique chez un patient atteint de cancer du poumon EGFR-muté
Duruisseaux, M. (2019) · Revue des Maladies Respiratoires Actualités · doi:10.1016/s1877-1203(19)30010-2
What the Oncologist Needs From the Pathologist for Immune Therapies
Bernicker, E. (2019) · Archives of Pathology & Laboratory Medicine · doi:10.5858/arpa.2019-0340-sa
Rapid progression of disease from immunotherapy following targeted therapy: insights into treatment management and sequence
Pharaon, R. R., Mambetsariev, I., Fricke, J., & Salgia, R. (2020) · Journal of Thoracic Disease · doi:10.21037/jtd.2019.08.14
[Immunotherapy in Epidermal Growth Factor Receptor-mutant Non-small Cell Lung Cancer].
Wang, X., & Zhong, D. (2019) · Europe PMC (PubMed Central) · doi:10.3779/j.issn.1009-3419.2019.08.11
Oncogene addiction and immune escape: friends or foes?
Abdayem, P., & Planchard, D. (2020) · Annals of Translational Medicine · doi:10.21037/atm-20-3036
Sequencing Therapy for Patients With Lung Cancer
Riely, G. J. (2020) · Journal of the National Comprehensive Cancer Network · doi:10.6004/jnccn.2020.5010
Première ligne des CBNPC avancés sans addiction oncogénique : quel traitement pour quel patient ?
Pérol, M. (2020) · Revue des Maladies Respiratoires Actualités · doi:10.1016/s1877-1203(20)30148-8
BRAF V600E mutant, PD-L1 TPS 90% NSCLC: 1st line treatment with targeted therapy
Yau, E. H. (2021) · Precision Cancer Medicine · doi:10.21037/pcm-2020-mnsclc-06
Beyond PACIFIC: Uncharted Waters
Juloori, A., & Vokes, E. E. (2021) · Journal of Thoracic Oncology · doi:10.1016/j.jtho.2021.02.006
MET Inhibitor is Expected to Overcome MET Amplification-Induced Immunotherapy Resistance in Non-Small Cell Lung Cancer
Ruan, J. (2021) · Asia-Pacific Journal of Oncology Nursing · doi:10.4103/apjon.apjon-2164

Authors: Lisberg, A., Cummings, A., Goldman, J. W., Bornazyan, K., Reese, N., Wang, T., Coluzzi, P., Ledezma, B., Mendenhall, M., Hunt, J., Wolf, B., Jones, B., Madrigal, J., Horton, J., Spiegel, M., Carroll, J., Gukasyan, J., Williams, T., Sauer, L., Wells, C., Hardy, A., Linares, P., Lim, C., Ma, L., Adame, C., & Garon, E. B.
Affiliations: University of California, Los Angeles (US)
Corresponding author: Garon, Edward B.
ORCID: Lisberg, A.
Cummings, A.
Goldman, J.W.
Bornazyan, K.
Spiegel, M.
Carroll, J.
Gukasyan, J.
Sauer, L.
Hardy, A.
Ma, L.
Garon, Edward B.
Venue: Journal of Thoracic Oncology
Publisher: Elsevier BV
Published: 2018-08
Volume: 13
Issue: 8
Pages: 1138-1145
ISSN: 1556-0864 (ISSN-L)
DOI: 10.1016/j.jtho.2018.03.035
PMC: PMC6063769
OpenAlex: W2889653218
Cited by: 580
References: 27
Citations by year: 2026: 29 · 2025: 63 · 2024: 78 · 2023: 74 · 2022: 81 · 2021: 87 · 2020: 78 · 2019: 71 · 2018: 19
FWCI: 48.03
Type: journal article
Language: en
Open access: bronze
doi.org
Licence: www.elsevier.com/tdm/userlicense/1.0/ (tdm)
www.elsevier.com/legal/tdmrep-license (tdm)
www.elsevier.com/open-access/userlicense/1.0/ (vor, 365 d)
Locations: Journal of Thoracic Oncology (publishedVersion)
PubMed (publishedVersion)
PubMed Central (acceptedVersion)
eScholarship (California Digital Library) (submittedVersion)
Funders: National Institutes of Health
Topics: Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Lung Cancer Treatments and Mutations
Health Sciences › Medicine › Oncology › Cancer Immunotherapy and Biomarkers
Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Lung Cancer Diagnosis and Treatment
Keywords: pembrolizumab, EGFR-mutant non-small cell lung cancer, PD-L1 expression, immune checkpoint inhibitors, objective response rate, treatment-related adverse events, pneumonitis, EGFR tyrosine kinase inhibitors
MeSH terms: Adult, Aged, Carcinoma, Non-Small-Cell Lung, Female, Humans, Lung Neoplasms, Male, Middle Aged, Mutation, Protein Kinase Inhibitors, B7-H1 Antigen, Antibodies, Monoclonal, Humanized, ErbB Receptors

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

A Phase II Study of Pembrolizumab in EGFR-Mutant, PD-L1+, Tyrosine Kinase Inhibitor Naïve Patients With Advanced NSCLC

Abstract

Overview

Integrity signals

Verification

Claims the paper makes

Claims other papers make about this one

Self-check

Citations

Cites

Cited by

Related

Metadata

Record

About these checks